Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
checkpoint inhibitors
Biotech
BioNTech sets survival standard in hard-to-treat cancer
BioNTech linked gotistobart to a median OS of 18.5 months, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
Nick Paul Taylor
Sep 14, 2026 4:15am
Boehringer axes MASH deal after OSE asset fails to show efficacy
Mar 2, 2026 2:16pm
Sensei shrinks workforce by 65% as layoff warning comes to pass
Nov 14, 2025 10:33am
Sensei drops sole clinical-stage cancer drug, plans layoffs
Oct 30, 2025 9:52am
GSK loses hope for CD226 cancer therapies, dropping ph. 2 assets
Oct 29, 2025 6:29am
Scancell picks winner from phase 2 cancer vaccine face-off
Jul 22, 2025 9:38am
